Recipharm’s new high speed filling line, designed for pre-filled syringes and cartridges, is expected to be operational by May 2023.
Recipharm, a global contract development and manufacturing organization, announced on Oct. 19, 2022 that it would be investing in a new high speed filling line for pre-filled syringes and cartridges at its sterile manufacturing facility in Wasserburg, Germany. The line, which is expected to be ready for its first good manufacturing practice batch run in May 2023, will be fully Annex 1 compliant and is designed to support both small and large volume projects.
According to a company press release, this decision was made as a result of increased customer demand in high growth fill formats. The Wasserburg facility specializes in producing more complex formats, ranging from lyophilization technology to aseptic filling into vials, syringes, and cartridges.
“The demand for pre-filled syringes is rapidly growing, with the projected market value by 2030 expecting to reach $6.5 billion,” said Marc Funk, CEO, Recipharm, in the release. “We are proud to be able to offer such a comprehensive service to our customers spanning device design, development and manufacturing to drug product fill & finish, and look forward to continuing to simplify the journey to market for our customers and of course helping patients access vital medicines.”
Source:
